James Dunbar is VP of Discovery Technology at BenevolentAI, leading teams to build and maintain platform capabilities that allow drug discovery scientists to use the Benevolent Platform™'s integrated multimodal biomedical data to improve their decision making and build the Company’s portfolio of drug programmes. His team maintains a high standard of scientific and technical quality in our tools and machine learning models that are used to explore and uncover disease mechanisms, and to prioritise and assess potential novel drug targets.
James holds an MPhys degree in Physics and a DPhil in Structural Bioinformatics, both from the University of Oxford. He conducted postdoctoral research at MedImmune and Roche before joining BenevolentAI as a Bioinformatics Data Scientist in 2017. During his DPhil and postdocs, he developed a suite of computational tools to aid the analysis and design of antibody therapeutics that continue to be widely used by the computational antibody design field. At BenevolentAI, he has led and contributed to the development of the Company’s core target discovery technology as well as led the successful collaboration with AstraZeneca to identify drug targets for chronic kidney disease.